MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Lewy bodies"

  • 2018 International Congress

    Parkinson’s disease anxiety is associated with Lewy bodies in the Anterior Cingulate

    N. Fischer, J. Hinkle, K. Perepezko, G. Pontone (Baltimore, MD, USA)

    Objective: The goal of this study is to determine if there is an association between anxiety and the presence and regional distribution of Lewy bodies…
  • 2018 International Congress

    Papez circuit atrophy in Dementia with Lewy Bodies

    E. Matar, S. Wong, R. Tan, O. Piguet, M. Hornberger, J. Krill, J. Hodges, G. Halliday (Sydney, Australia)

    Objective: In this ex-vivo study, we aimed to assess atrophy in regions and subregions of the Papez Circuit, a network important for memory function, in…
  • 2018 International Congress

    Characterization of color vision impairment in Lewy Body Diseases

    T. Tousi, F. Flanigan, K. Khosravi (Cleveland, OH, USA)

    Objective: We sought to characterize the prevalence of color vision impairment in DLB patients and investigate how color vision impairment in DLB patients was associated…
  • 2018 International Congress

    Lewy body disease with visual hallucination: Optic radiation abnormalities on phase difference-enhanced imaging (PADRE)

    M. Miyata, S. Kakeda, T. Yoneda, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)

    Objective: We assessed structural abnormalities of optic radiation (OR) in healthy subjects (HS) and dementia with lewy body (DLB) patients (with visual hallucination) (VH) on…
  • 2018 International Congress

    Prevalence and influence of co-pathologies in patients with autopsy-confirmed Lewy body disorders: A systematic review

    D. Breen, E. Ravid, A. Lang, J. Miyasaki, R. Camicioli (Toronto, ON, Canada)

    Objective: To determine the prevalence of selected co-pathologies in patients with Lewy Body disorders, as well as their influence on disease expression. Background: The presence…
  • 2017 International Congress

    Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease

    E. Tsika, E. Gabellieri, A. Davranche, C. Boudou, M. Ravache, L. Grasso, S. Nampally, H. Haddouk, J. Wettstein, A. Pfeifer, A. Muhs (Lausanne, Switzerland)

    Objective: To develop small molecular weight compounds (SMEs) as disease-modifying agents, which are designed to arrest or even reverse the aggregation process of alpha-synuclein (aSyn)…
  • 2017 International Congress

    Impaired Color Vision in Patients with DLB or Prodromal DLB.

    B. Tousi, P. Flanigan, M. Khosravi (Cleveland, OH, USA)

    Objective: We sought to characterize the prevalence of color vision impairment in DLB patients and investigate how color vision impairment in DLB patients was associated with other…
  • 2017 International Congress

    Association of arterial stiffness with cognition in patients with Lewy body disorder

    J.Y. LEE, D.-W. Ryu, J.-S. Kim (Seoul, Republic of Korea)

    Objective: We aimed to investigate the association between arterial stiffness and cognitive function in patients with Lewy body disorder (LBD), including Parkinson disease (PD) and…
  • 2017 International Congress

    Striatal dopamine transporter abnormalities in pure autonomic failure and speculation about the relationship with Lewy bodies

    M. Yogo, M. Morita, M. Suzuki (Tokyo, Japan)

    Objective: To reveal dopamine transporter (DAT) abnormalities in pure autonomic failure (PAF) and speculate about the relationship with the Lewy body progression pathway.    Background:…
  • 2017 International Congress

    Characterization of Noncoding Variant(s) Driving Genome-Wide Association of the PARK10 Locus in Autopsy-Proven Parkinson Disease and Controls.

    J. Vance, K. Nuytemans, D. Gveric, L. Gomez, G. Beecham, E. Martin, W. Scott (Miami, FL, USA)

    Objective: Confirm the PARK10 locus as a major GWAS locus in autopsy-confirmed (AC) PD and AC controls and identify potential noncoding variants driving the association. …
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley